Loading company…
San Francisco biotech using its ToR FLEx platform to find drugs against protein targets that traditional approaches cannot reach.
SyntheX, Inc. was founded in 2016 and is headquartered in San Francisco, US. Its ToR FLEx platform engineers cells to run functional selection of compounds that modulate difficult protein targets, and it works with pharmaceutical and biotech partners. The company has completed three deals, and on April 20, 2017 it raised USD 6.2 million in Seed funding led by Morgan Noble, with support from 8VC, Oriza Ventures and SOSV. Co-founder Maria Soloveychik currently serves as CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in